Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia an... (there are approximately 44000 new cases ...)

HOME >> MEDICINE >> NEWS

Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma

Date:12/6/2008

there are approximately 44,000 new cases and 22,000 deaths associated with leukemia in the United States.

Lymphoma is cancer of the lymphatic system that begins with a change in the lymphocytes, impairing the ability of the body's immune system to fight infection. Lymphomas are divided into two categories: Hodgkin lymphoma and non-Hodgkin lymphoma. Most non-Hodgkin lymphomas are B-cell lymphomas, which are further classified into 14 different sub-types based on the stage of cell development during which the B cell has been affected. The rest are T-cell lymphomas, which affect another type of white blood cell. There are approximately 66,000 new cases of lymphoma and nearly 20,000 deaths each year in the United States according to the National Cancer Institute.

Fostamatinib Disodium (FosD), an Oral Inhibitor of SYK, isWell-Tolerated and Has Significant Clinical Activity in Diffuse Large B-CellLymphoma and ChronicLymphocytic Leukemia

[Abstract #3]

Jonathan W.Friedberg, M.D., James P.Wilmot Cancer Center, Rochester, NY

Results of the first clinical study examining the use of fostamatinib disodium, an investigational treatment that targets a protein called SYK (spleen tyrosine kinase), showed that the new agent represents a safe and novel therapeutic approach that should be further developed for the treatment of B-cell non- Hodgkin lymphoma. In the study, fostamatinib disodium, administered as a tablet, produced significant responses in patients who had failed previous treatments for diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as prolonged stable disease in patients with follicular lymphoma.

Following a phase I dose-limiting study of 13 patients, the regimen of a 200 mg twice-daily dose of fostamat
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Novel therapeutic approaches may improve patient outcomes in several platelet disorders
2. Bone Marrow-Derived Stem Cells May Offer Novel Therapeutic Option for Skin Disorder
3. Bone marrow-derived stem cells may offer novel therapeutic option for skin disorder
4. Novel Anticoagulants Will Garner More Than Three-Quarters of the Atrial Fibrillation Drug Market in 2017
5. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
6. Novel Techniques Offers New Freedom to Patients with Parkinson's Disease, Epilepsy, Dystonia, and Tremor
7. USC researchers identify novel approach for suppressing prostate cancer development
8. Studies show novel device may enhance chemotherapy treatment in brain tumors
9. Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
10. Labopharms NDA for Novel Trazodone Formulation accepted for review by FDA
11. E6 Ventures Invests in Novel Coatings Developer, Diamond Hard Surfaces Ltd

Post Your Comments:

Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia an...(there are approximately 44000 new cases ...),Health